Kala Pharmaceuticals competitorsClear all

Kala Pharmaceuticals's top competitors include Biogen, MyoKardia, Otonomy and Alimera Sciences.
Kala Pharmaceuticals
Kala Pharmaceuticals
Kala is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Alimera Sciences
Alimera Sciences
Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
Founding Date
Founding Date
2009
Founding Date
1978
Founding Date
2012
Founding Date
2008
Founding Date
2003
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Watertown, US HQ
Waltham, US
Locations
Cambridge, US HQ
Vicente López, AR
North Ryde, AU
Wien, AT
Machelen, BE
São Paulo, BR
Mississauga, CA
see more
Locations
South San Francisco, US HQ
Brisbane, US
Locations
San Diego, US HQ
Locations
Alpharetta, US HQ
Berlin, DE
Dublin 2, IE
Lisboa, PT
Hampshire, GB
Employees
Employees
3748% increase
Employees
7,4005% decrease
Employees
23542% increase
Employees
49
Employees
1222% decrease
Valuation ($)
Valuation ($)
501.2 m
Valuation ($)
43.1 b
Valuation ($)
6.9 b
Valuation ($)
164.5 m
Valuation ($)
25.6 m
Twitter followers
Twitter followers
N/A
Twitter followers
33.9 k
Twitter followers
1 k
Twitter followers
226
Twitter followers
2.3 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
57
Number of tweets (last 30 days)
15
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
35.8
Average likes per tweet (last 30 days)
20.7
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
345658
Alexa Website Rank
254464
Alexa Website Rank
239431
Alexa Website Rank
339305
Alexa Website Rank
344430
Employee Rating
Employee Rating
5
Employee Rating
3.8
Employee Rating
4.2
Employee Rating
4.3
Employee Rating
3.8

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$14.4b (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
$600k (FY, 2019)
Revenue (est.)
$53.9m (FY, 2019)
Cost of goods
Cost of goods
N/A
Cost of goods
$2b (FY, 2019)
Cost of goods
N/A
Cost of goods
$912k (FY, 2019)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$12.4b (FY, 2019)
Gross profit
N/A
Gross profit
($312k) (FY, 2019)
Gross profit
N/A
Net income
Net income
($33.2m) (FY, 2016)
Net income
$5.9b (FY, 2019)
Net income
($276.2m) (FY, 2019)
Net income
($44.7m) (FY, 2019)
Net income
($10.4m) (FY, 2019)

Operating

Patents (US)
Patents (US)
6 (FY, 2016)
Patents (US)
21 (FY, 2019)
Patents (US)
2 (FY, 2018)
Patents (US)
N/A
Patents (US)
N/A
Patents Issued
Patents Issued
N/A
Patents Issued
34 (FY, 2019)
Patents Issued
N/A
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
11 (Q2, 2020)
Phase I Trials Products
1 (FY, 2018)
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
10 (Q2, 2020)
Phase II Trials Products
2 (FY, 2018)
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q2, 2020)
Phase III Trials Products
1 (FY, 2018)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Pre-Clinical Phase Products
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
3 (FY, 2018)
Pre-Clinical Phase Products
1 (FY, 2016)
Pre-Clinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
$ 114.2m
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 153.4m
Total funding raised
$ 232.6m
For sources of this data, please see the company profile

View company profiles

Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Otonomy
HQ
San Diego, US
Employees
49

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Alimera Sciences
HQ
Alpharetta, US
Employees
122↓ 2% decrease

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

View company